Eloxx Pharmaceuticals Ltd. and Sevion Therapeutics, Inc. have completed their acquisition transaction, effective December 19. The company will be known as Eloxx Pharmaceuticals, Inc. “This acquisition transaction marks a significant milestone as Eloxx transitions from a private to a publicly-traded company with significantly increased financial resources,” said Silvia Noiman, Ph.D., MBA, founder and Chief Executive Officer of Eloxx Pharmaceuticals. “We are now better positioned to advan...